The article mentions chronic pelvic pain syndrome / prostatitis.
BioXell and Lay Line Genomics announce License Agreement for Anti-TrkA Antibody against Pain
WEBWIRE – Monday, February 13, 2006
Milan, Rome, Italy, February 13th, 2006 –BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor (NGF), a key mediator of pain. According to the agreement, BioXell will take MNAC13 through development and potential commercialisation, in exchange for an undisclosed upfront payment, milestones and royalties to LLG.
....
In addition to oncological pain and chronic inflammatory conditions such as osteoarthritis, we believe that MNAC13 may find an extremely promising field of application in Chronic Pelvic Pain Syndromes (CPPS), such as interstitial cystitis and chronic non-bacterial prostatitis.”